The involvement of Nek2 and Notch in the proliferation of rat adrenal cortex triggered by POMC-derived peptides.

The adrenal gland is a dynamic organ that undergoes constant cell turnover. This allows for rapid organ remodeling in response to the physiological demands of the HPA axis, which is controlled by proopiomelanocortin (POMC)-derived peptides, such as adrenocorticotropic hormone (ACTH) and N-Terminal peptides (N-POMC). In the rat adrenal cortex, POMC-derived peptides trigger a mitogenic effect, and this process increases cyclins D and E, while inhibiting p27Kip1. The goal of the present study was to further explore the mitogenic effect of ACTH and synthetic N-POMC1-28 peptides by investigating the differences in the expression of key genes involved in the cell cycle of the rat adrenal cortex, following inhibition of the HPA axis. Moreover, we evaluated the differences between the inner and outer fractions of the adrenal cortex (ZF-fraction and ZG-fraction) in terms of their response patterns to different stimuli. In the current study, the inhibition of the HPA axis repressed the expression of Ccnb2, Camk2a, and Nek2 genes throughout the adrenal cortex, while treatments with POMC-derived peptides stimulated Nek2, gene and protein expression, and Notch2 gene expression. Furthermore, Notch1 protein expression was restricted to the subcapsular region of the cortex, an area of the adrenal cortex that is well-known for proliferation. We also showed that different regions of the adrenal cortex respond to HPA-axis inhibition and to induction with POMC-derived peptides at different times. These results suggest that cells in the ZG and ZF fractions could be at different phases of the cell cycle. Our results contribute to the understanding of the mechanisms involved in cell cycle regulation in adrenocortical cells triggered by N-POMC peptides and ACTH, and highlight the involvement of genes such as Nek2 and Notch.

Introduction

The adrenal gland is composed of two distinct regions: the cortex and the medulla. The cortex consists of three concentric zones: the zona glomerulosa (ZG), the zona fasciculata (ZF), and the zona reticularis (ZR). The adrenal cortex requires stimuli from the adrenocorticotropic hormone (ACTH) precursor pro-opiomelanocortin (POMC) for adrenocortical maintenance and remodeling. Several other peptides are secreted from the anterior pituitary, including pro-gamma-MSH. Pro-gamma-MSH potentiates the steroidogenic actions of ACTH, triggering an increase of cholesterol and cholesterol ester hydroxylase activity [1]–[3]. Moreover, the N-terminal sequences of pro-gamma-MSH that do not contain the MSH-gamma sequence (known as the N-terminal portion of POMC, or N-POMC) are able to induce cell proliferation in the adrenal cortex [4] [5]. Previous studies have shown that N-POMC1–28 and N-POMC2–54 peptides are potent mitogens, both in vitro [4] and in vivo [6]. Recent work from our group has shown that synthetic N-POMC1–28 induced in vivo S-phase entry in the entire rat adrenal cortex by up-regulating cyclins D and E [7] [8]. Moreover, N-POMC1–28 induced proliferation of rat adrenal cells in primary culture via the ERK1/2 pathway [9].

It is well-known that inhibition of the HPA axis by dexamethasone (DEX) or hypophysectomy can cause atrophy only in the innermost portion of the adrenal cortex [10]–[13]. However, the mechanisms involved in the regulation of cell cycle genes in adrenal cells after the absence of POMC-derived peptides remain poorly understood. This study aimed to evaluate the expression pattern of 86 genes associated with cell cycle regulation in the adrenal cortex of dexamethasone-treated rats after administration of ACTH or synthetic N-POMC1–28 peptides (these N-POMC peptides contain correctly aligned disulfide bonds in cysteines [N-POMCCys] or a linear structure with methionines [N-POMCMet]). Moreover, we evaluated the differences between the inner and outer fractions of the adrenal cortex in terms of their response patterns to different stimuli, as well as the differences and similarities between the proliferative effects triggered in the adrenal cortex by ACTH and N-POMC peptides. Our results highlight the involvement of some key genes in adrenocortical cellular proliferation, such as Nek2 and Notch.

Materials and Methods

Animals

Male Sprague-Dawley rats with an average weight of 250±30 g were obtained from the Institute of Biomedical Sciences of the University of São Paulo and maintained in a temperature-controlled environment and 12-h light/dark cycle. The study was approved by the Animal Experimentation Ethics Committee at the University’s Institute of Biomedical Sciences. The animals were fed with standard rat food and received water ad libitum. All experimental procedures were conducted between 9 and 11 am; the rats were euthanized by decapitation and adrenal glands were harvested.

N-POMC1–28 peptide synthesis

N-POMC1–28 peptides were synthesized with cysteine (N-POMCCys) or methionine (N-POMCMet). The N-POMCCys peptide was synthesized and characterized by Bachem America Inc. (Torrance, CA, USA) and contained correctly aligned disulfide bridges in the cysteine 2–24 and 8–20 positions. In order to avoid undefined disulfide bonds, the N-POMCMet peptide was synthesized and characterized in the Department of Biochemistry and Biophysics at the Federal University of São Paulo (UNIFESP) by replacing cysteine with methionine.

Dexamethasone, ACTH, and N-POMC1–28 treatments

The animals were treated as previously described in [8]. Briefly, a concentration of 50 µg/100 g of body weight (BW) of Dexamethasone (DEX) (Aché Laboratórios Farmacêuticos, Campinas, SP, Brazil) was administered intraperitoneally, once a day at 9 am for 2 days, with the purpose of inhibiting the HPA axis. The control animals received saline injections and followed the same treatment regimen as the experimental animals. Subsequently, DEX-treated rats were divided into four groups (n = 4–5) and received a single injection of ACTH, N-POMCCys, N-POMCMet, or saline. The ACTH, N-POMCCys, and N-POMCMet treatments were administered at a concentration of 10−7 M in the dose of 100 µl/100 g BW.

Preparation of protein lysates

The preparation of protein lysates was performed as described in [7]. Briefly, at 6 hours post treatment, the adrenal glands were removed and gently decapsulated to separate the capsule/zona glomerulosa (ZG fraction, composed mainly of ZG cells) from the zona fasciculata/reticularis and medulla (ZF fraction, composed mainly of ZF cells). The medulla was removed from the ZF fraction and the samples were lysed in ice-cold RIPA and protease inhibitors. Protein concentrations were quantified with the Bradford assay. Previously published data concerning the quality of preparation and separation of the adrenal fractions, showed that the contamination between different fractions was minimal and acceptable [7].

Nek2 protein expression

Total lysate protein samples from the ZG and ZF fractions (30 µg from each) were sorted in 10% SDS-PAGE. To test the Nek2 protein isoforms, we used a commercial HeLa nuclear extract (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for positive control of the antibody. We also obtained Y1 and primary rat adrenal cell culture total protein extracts, as described in [9]. After electrophoresis, the gel was electroblotted onto Hybond-C nitrocellulose membranes using a semi-dry Bio-Rad apparatus. Non-specific sites were blocked overnight at 4°C with 5% dried non-fat milk dissolved in TBS (150 mM NaCl, 10 mM Tris, 1% Tween 20, pH 7.5). The membranes were subsequently incubated with anti-Nek2 (1∶1000; Santa Cruz) or β-actin (1∶2000, Santa Cruz) for two hours at room temperature. Proteins were detected using chemiluminescent secondary peroxidase-conjugated anti-rabbit or anti-mouse polyclonal antibodies (ECL-Amersham-Pharmacia, Piscataway, NJ, USA). The immunoblot results were quantified by densitometry using the Gel-Pro Imager and Gel-Pro Imager kit Version 1.0 quantification program for Windows. The average and standard error were calculated for the data obtained from each fraction. Ponceau staining was used to monitor protein transfer amounts and total protein loaded.

Immunohistochemistry of Nek2 and Notch expression

The rats were euthanized 6 h after the final treatments; adrenal glands were removed, fixed in 4% paraformaldehyde in a solution of 0.1 M phosphate buffered saline (PBS; pH 7.4) for 8 h at room temperature, and subsequently immersed in 6% sucrose PBS for 12 h. The fixed and deparaffinized sections were rehydrated through a graded ethanol series, washed with sterile Milli-Q water, PBS, and PBS with 0.5% hydrogen peroxide. Sections were incubated for 10 minutes in boiling citrate buffer (pH 6.0) for antigen retrieval, and the background staining was blocked using a commercial blocker solution (Background Blocker; Diagnostic BioSystems, Pleasanton, CA, USA). These sections were washed and incubated in PBS with anti-Nek2 1∶200 (Santa Cruz), or anti-Notch 1 1∶100 (Cell Signaling Technology, Inc. Danvers, MA, USA) or anti-Notch 2 1∶100 (Cell Signaling) or even Notch 3 1∶500 (Cell Signaling). The immune complexes were detected by immunoperoxidase staining using the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) and visualized with diaminobenzidine (Sigma Fast; Sigma Aldrich, St. Louis, MO, USA) followed by counterstaining with Harris’ hematoxylin and a saturated solution of lithium carbonate. The adrenal sections incubated in non-immune primary sera tested negative (data not shown).

Total RNA isolation and PCR array

Two hours after final treatments with Saline, ACTH, or N-POMC peptides, the rats were decapitated and their adrenal glands were removed and separated into ZG and ZF fractions. The total RNA was isolated using Trizol extraction according to the manufacturer’s instructions (Life Technologies, USA). The cDNA synthesis was prepared according to the PCR array manufacturer’s instructions (Sabiosciences – Qiagen, Germantown, MD USA). cDNA was mixed with SYBER Green MIX provided by the manufacturer and applied in the PCR array plates (Rat Cell Cycle PARN-020). The assays were performed on a standard real-time PCR device ABI7500 (Applied Biosystems – Life Technology). Data were analyzed using online software provided by the PCR array manufacturer.

Statistical data analyses

For the Western-Blotting assay, statistical comparisons of three independent immunoblot results were tested using analysis of variance (ANOVA) followed by the Tukey-Kramer Multiple Comparisons Test. For the PCR array experiments, the p values were calculated based on a Student’s t-test of the replicate 2∧(−Delta Ct) values for each gene in the control and treatment groups. Values of p≤0.05 were considered statistically significant. The results corresponded to three independent experiments.

Ethics Statement

This study was carried out in full accordance with the ethical principles of animal experimentation adopted by the Brazilian Society of Laboratory Animals in Science and was approved by the ethics committee on animal use of the Institute of Biomedical Sciences under protocol number 156, page 112, book 02.

Results

HPA-axis inhibition reduced Nek2, Ccnb2, and Camk2b expression in the entire cortex

To evaluate the effects of HPA-axis inhibition by dexamethasone (DEX) in the expression of genes involved in the cell cycle of the adrenal cortex, we used a real-time RT-PCR-based plate assay. The ZG and ZF fractions showed distinct profiles of gene expression after HPA-axis inhibition with Dex treatment (Figure 1A). Among all significantly regulated genes, three genes were significantly (p<0.05) down-regulated in both fractions of the cortex: Nek2, Ccnb2, and Camk2b (Figure 1B). Nek2 was the most repressed gene, irrespective of the adrenal fraction (ZG: −17.8 fold and ZF: −12.4 fold). All significantly regulated genes are listed in Table 1. In order to validate the expression of Nek2 on a protein level, we first evaluated the protein isoform found in the rat adrenal cortex. Our results show that the isoform 2 (Nek2b ∼38 kDa) was expressed in the rat adrenal gland (Figure S1). The expression of Nek2b was reduced in both fractions after HPA-axis inhibition: 0.57-fold and 0.36-fold in the ZG and ZF fractions, respectively (Figure 1C). Immunohistochemistry revealed no expression of Nek2b in the capsule, and a decreased expression in the entire cortex following HPA-axis inhibition (Figure 2).

Figure 1

Clustergram showing the expression profile of significantly (p<0.05) altered genes related to the cell cycle in adrenal ZF fraction or ZG fraction after inhibition of the HPA axis with DEX for two days (50 µg/100 g BW) (A) Correlation of up- or down-regulated genes in ZF fraction and ZG fraction; genes regulated in both DEX and control treatments are presented in the figure intersection (B).

Analysis of Nek2b protein expression in adrenal ZF fraction and ZG fraction after inhibition of HPA axis with DEX (C). Adrenal glands were separated in two fractions (ZG and ZF), and total protein or total RNA, respectively, was extracted for the immunoblotting or PCR array analysis. Control animals received saline only (Control). *p<0.05, n = 3.

Table 1

Genes significantly regulated in the ZG and ZF fractions of the adrenal cortex after inhibition of the HPA axis.

ZG Fraction After HPA Axis Inhibition
Gene Symbol	Gene	Fold Regulation	p-value
Tp53	Tumor protein p53	1.9386	0.034216
Cdkn1a	Cyclin-dependentkinase inhibitor 1A	1.879	0.001773
Ccnd1	Cyclin D1	1.7471	0.005476
Ccnc	Cyclin C	1.7451	0.009108
Terf1	Telomeric repeatbinding factor(NIMA-interacting) 1	1.6837	0.040843
Ddit3	DNA-damageinducible transcript 3	1.6415	0.000001
Taf10	TAF10 RNA polymeraseII. TATA box bindingprotein (TBP)-associated factor	1.5	0.033599
Gadd45a	Growth arrest andDNA-damage-inducible. alpha	1.4692	0.005312
Prm1	Protamine 1	1.454	0.022124
Ppp3ca	Protein phosphatase 3.catalytic subunit. alpha isoform	1.4439	0.018036
Camk2a	Calcium/calmodulin-dependentprotein kinase II alpha	−1.6702	0.041303
Npm2	Nucleophosmin/nucleoplasmin 2	−1.7715	0.031786
Camk2b	Calcium/calmodulin-dependentprotein kinase II beta	−1.9611	0.012154
Cdk2	Cyclin dependent kinase 2	−2.1535	0.046664
Rbl1	Retinoblastoma-like 1 (p107)	−2.5462	0.044093
Cdk4	Cyclin-dependent kinase 4	−2.5491	0.046248
Cdc25b	Cell division cycle 25homolog B (S. pombe)	−2.7069	0.041175
Ccnf	Cyclin F	−3.5677	0.046238
Brca1	Breast cancer 1	−3.5925	0.014395
Ccne1	Cyclin E1	−3.6723	0.033051
Rad51	RAD51 homolog(RecA homolog.E. coli) (S. cerevisiae)	−4.302	0.048942
E2f1	E2F transcription factor 1	−5.6962	0.0074
Ccna2	Cyclin A2	−7.2518	0.01107
Ccnb1	Cyclin B1	−9.2642	0.025219
Ccnb2	Cyclin B2	−12.8468	0.014697
Nek2	NIMA (never in mitosis gene a)-related expressed kinase 2	−17.8973	0.006768
ZF Fraction After HPA Axis Inhibition
Gene Symbol	Gene	Fold Regulation	p-value
Wee1	Wee 1 homolog (S. pombe)	3.5431	0.030867
Gpr132	G protein-coupled receptor 132	3.1711	0.023048
Atm	Ataxia telangiectasiamutated homolog (human)	2.2763	0.031384
Sfn	Stratifin	2.0922	0.015251
Smc1a	Structural maintenanceof chromosomes 1A	−1.2058	0.00984
Stag1	Stromal antigen 1	−1.2354	0.037677
Ppm1d	Protein phosphatase 1Dmagnesium-dependent.delta isoform	−1.3755	0.047927
Pes1	escadillo homolog 1.containing BRCT domain (zebrafish)	−1.429	0.000259
Cdc25a	Cell division cycle 25homolog A (S. pombe)	−1.434	0.000137
Dst	Dystonin	−1.5637	0.008329
Rad21	RAD21 homolog (S. pombe)	−1.6472	0.015744
Ccnc	Cyclin C	−1.6644	0.021064
Rbl2	Retinoblastoma-like 2	−1.7112	0.004351
Mre11a	MRE11 meiotic recombination11 homolog A (S. cerevisiae)	−1.8404	0.001225
Ddit3	DNA-damage inducible transcript 3	−1.8661	0.046409
Camk2b	Calcium/calmodulin-dependentprotein kinase II beta	−1.8725	0.002969
Ccna1	Cyclin A1	−1.8856	0.00258
Dnajc2	DnaJ (Hsp40) homolog.subfamily C. member 2	−1.9862	0.047149
Mad2l1	MAD2 mitotic arrestdeficient-like 1 (yeast)	−2.0209	0.011379
Taf10	TAF10 RNA polymerase II.TATA box binding protein(TBP)-associated factor	−2.0491	0.032413
Ran	RAN. member RAS oncogene family	−2.166	0.032983
Tp53	Tumor protein p53	−2.1735	0.010038
Ccnb2	Cyclin B2	−2.3784	0.032474
Cdkn2b	Cyclin-dependent kinaseinhibitor 2B (p15. inhibits CDK4)	−2.7226	0.005969
Tp63	Tumor protein p63	−2.7702	0.0034
Inha	Inhibin alpha	−2.8879	0.016507
Pcna	Proliferating cell nuclear antigen	−2.9079	0.019438
Nek2	NIMA (never in mitosis gene a)-relatedexpressed kinase 2	−12.4235	0.01

Figure 2

Immunolocalization of Nek2b expression in the adrenal cortex after HPA inhibition.

Adrenal sections were obtained from rats treated with: (A) saline only or (B) DEX for two days (50 µg/100 g BW). Nek2b-positive cells were stained brown. Sections were counterstained with Harris’ hematoxylin and differentiated with a saturated solution of lithium carbonate. Bars 10 µm.

ACTH and N-POMC peptides induce distinct gene expression profiles in the outer and inner zones of the adrenal cortex

We report results for treatments with ACTH and N-POMC peptides on genes that were significantly (p<0.05) up- or down-regulated. In the ZG fraction, treatment with ACTH promoted a distinct profile of gene expression compared to treatment with N-POMC peptides (Figure 3A). These distinct responses could be partially due to the larger number of repressed genes in common between treatments with the two N-POMC peptides (14) compared to those repressed in common between treatment with ACTH and either N-POMC peptide (4). Only three genes were down-regulated in all treatments: Ccnc, Cdkn1a, and Pkd1. Our data also reveal that ACTH up-regulated the expression of Camk2 (as did N-POMCCys) and of Dnajc2 (as did N-POMCMet). Moreover, Inha expression was up-regulated after stimulation with both N-POMC peptides (Figure 3B). When we analyzed cell cycle-related genes, we observed that ACTH up-regulated four genes related to the G1 phase (Camk2a, Ccne1, Cdk4, and Gpr132) and two related to the G2 phase (Chek1 and Dnajc2). Treatment with N-POMCMet up-regulated the expression of genes related to the S phase (Mcm3 and Mre11a), the G2 phase (Dnajc2), and the M phase (Ran, Psmg2, and Pes1), whereas N-POMCCys up-regulated the expression of only one gene (Camk2a), which is related to the G1 phase (Figure 3C). Furthermore, N-POMCCys down-regulated more genes (7) related to a late phase of the cell cycle (M-phase) than ACTH (2) or N-POMCMet (3). The list of all significantly altered genes in the ZG fraction, including their fold regulation data, is available in Table 2. In the ZF fraction, the clustergram based only on significantly altered genes reveals that N-POMCCys treatment promoted a distinct pattern of gene expression when compared to the N-POMCMet and ACTH treatments (Figure 4A). Also, when we analyzed the genes that were regulated in common by the different treatments, we observed that Nek2 was up-regulated in all three treatments. Stag1, Mdm2, Casp3, Dnajc2, and Nfatc1 were up-regulated after treatment with both ACTH and N-POMCMet, whereas Ppm1d was up-regulated after treatment with either ACTH or N-POMCCys. Among the genes down-regulated in common between the treatments with POMC-derived peptides, only Camk2a was repressed after treatment with ACTH or N-POMCCys. Interestingly, N-POMCMet did not repress the expression of any gene (Figure 4B). When we analyzed genes related to specific phases of the cell cycle, we observed that ACTH up-regulated genes related to the G1 phase (Nfatc1), the G2 phase (Ppm1d and Dnajc2), and the M phase (Nek2 and Stag1). N-POMCMet up-regulated genes related to the G1 phase (Nfatc1), the G2 phase (Dnajc2), and the M phase (Nek2, Rad21, Shc1, and Stag1). On the other hand, N-POMCCys treatment up-regulated the expression of genes related to the S phase (Msh2 and Sumo1) and the M phase (Ccna1 and Nek2). Concomitantly with these up-regulations, ACTH treatment repressed genes related to the G1 phase (Camk2a, Ccnd1, and Ppp3ca), the S phase (Rad51), the G2 phase (Ccnf), and the M phase (Prm1 and Wee1). Also, N-POMCCys treatment down-regulated genes related to the G1 phase (Camk2a and Slfn1) and the M phase (Ccna2 and Ccnb1), as shown in Figure 4C. All significantly altered genes in the ZF fraction, including their fold regulation data, are listed in Table 3.

Figure 3

Results of the PCR array for cell cycle related genes in the ZG fraction.

Clustergram showing the expression profile of significantly (p<0.05) altered genes related to the cell cycle in the adrenal ZG fraction after inhibition of HPA axis with DEX for two days (50 µg/100 g BW), followed by ACTH or N-POMCMet or N-POMCCys treatments (A). Correlation of up- or down-regulated genes in the ZG fraction after treatments, showing the number of genes regulated by both treatments with POMC-derived peptides (B). Up- or down-regulated genes related to specific cell cycle phases after ACTH, N-POMCMet, or N-POMCCys treatments (C). G1: G1 phase and G1/S transition; G2: G2 phase; S: S phase and DNA replication; M: M phase.

Table 2

Genes significantly regulated in the ZG fraction of the adrenal cortex after inhibition of the HPA axis followed by treatments with ACTH, N-POMCMet, or N-POMCCys.

ZG Fraction: ACTH
Gene Symbol	Gene	Fold Regulation	p-value
Camk2a	Calcium/calmodulin-dependent protein kinase II alpha	3.0417	0.000054
Cdk4	Cyclin-dependent kinase 4	1.9117	0.011247
Dst	Dystonin	1.8402	0.013247
Ppm1d	Protein phosphatase 1D magnesium-dependent. delta isoform	1.8084	0.006493
Pmp22	Peripheral myelin protein 22	1.58	0.004287
Rad9	RAD9 homolog (S. pombe)	1.5261	0.026327
Chek1	CHK1 checkpoint homolog (S. pombe)	1.3946	0.038051
Ccne1	Cyclin E1	1.3866	0.044238
Abl1	C-abl oncogene 1. receptor tyrosine kinase	1.3409	0.010445
Dnajc2	DnaJ (Hsp40) homolog. subfamily C. member 2	1.2555	0.035768
Notch2	Notch homolog 2 (Drosophila)	1.1974	0.010077
Gpr132	G protein-coupled receptor 132	1.0942	0.024599
Ccnc	Cyclin C	−1.4141	0.042834
Cdkn1a	Cyclin-dependent kinase inhibitor 1A	−1.4708	0.024637
Ccnd1	Cyclin D1	−1.5074	0.02811
Prm1	Protamine 1	−1.5085	0.038924
Msh2	MutS homolog 2 (E. coli)	−1.6135	0.027143
Pkd1	Polycystic kidney disease 1 homolog (human)	−1.8617	0.000053
Ccna1	Cyclin A1	−2.5344	0.012597
ZG Fraction: N-POMCMet
Gene Symbol	Gene	Fold Regulation	p-value
Mre11a	MRE11 meiotic recombination 11 homolog A (S. cerevisiae)	1.8348	0.021743
Psmg2	Proteasome (prosome. macropain) assembly chaperone 2	1.824	0.007304
Pcna	Proliferating cell nuclear antigen	1.6431	0.000977
Pes1	Pescadillo homolog 1. containing BRCT domain (zebrafish)	1.598	0.047391
Inha	Inhibin alpha	1.5662	0.016083
Dnajc2	DnaJ (Hsp40) homolog. subfamily C. member 2	1.4394	0.037783
Cdk5rap1	CDK5 regulatory subunit associated protein 1	1.4382	0.003531
LOC367976	Similar to DNA replication licensing factor MCM3(DNA polymerase alphaholoenzyme-associated protein P1) (P1-MCM3)	1.3475	0.021984
Ran	RAN. member RAS oncogene family	1.2062	0.020662
Ccnb2	Cyclin B2	−1.2335	0.012467
Ccnc	Cyclin C	−1.2537	0.014855
Ccnf	Cyclin F	−1.2646	0.031889
Ccne1	Cyclin E1	−1.4087	0.034054
Bcl2	B-cell CLL/lymphoma 2	−1.4235	0.034361
Rad21	RAD21 homolog (S. pombe)	−1.4703	0.001876
Rbl2	Retinoblastoma-like 2	−1.4703	0.017071
Gpr132	G protein-coupled receptor 132	−1.4714	0.000172
Stag1	Stromal antigen 1	−1.4994	0.018796
Ppp3ca	Protein phosphatase 3. catalytic subunit. alpha isoform	−1.5327	0.007328
Cdkn1b	Cyclin-dependent kinase inhibitor 1B	−1.5434	0.020993
Ppp2r3a	Protein phosphatase 2. regulatory subunit B”. alpha	−1.5667	0.010109
Itgb1	Integrin. beta 1	−1.7364	0.009488
Ak1	Adenylate kinase 1	−1.8606	0.000275
E2f3	E2F transcription factor 3	−1.8675	0.011247
RGD1566319	Similar to Sestrin 2 (Hi95)	−1.8804	0.000178
Apbb1	Amyloid beta (A4) precursor protein-binding. family B. member 1 (Fe65)	−1.8871	0.015075
Pkd1	Polycystic kidney disease 1 homolog (human)	−1.9341	0.00016
Cdkn1a	Cyclin-dependent kinase inhibitor 1A	−2.0881	0.007196
Cdkn2a	Cyclin-dependent kinase inhibitor 2A	−2.202	0.010674
ZG Fraction: N-POMCCys
Gene Symbol	Gene	Fold Regulation	p-value
Camk2a	Calcium/calmodulin-dependent protein kinase II alpha	1.7687	0.001738
Gadd45a	Growth arrest and DNA-damage-inducible. alpha	1.594	0.031285
Inha	Inhibin alpha	1.455	0.014103
Ppp3ca	Protein phosphatase 3. catalytic subunit. alpha isoform	−1.311	0.028009
Ppp2r3a	Protein phosphatase 2. regulatory subunit B”. alpha	−1.4132	0.022207
Terf1	Telomeric repeat binding factor (NIMA-interacting) 1	−1.433	0.023569
Ccnc	Cyclin C	−1.4546	0.016437
Tfdp2	Transcription factor Dp-2 (E2F dimerization partner 2)	−1.4614	0.017254
E2f3	E2F transcription factor 3	−1.5025	0.016275
Shc1	SHC (Src homology 2 domain containing) transforming protein 1	−1.5025	0.01852
Itgb1	Integrin. beta 1	−1.5447	0.023496
Rbl2	Retinoblastoma-like 2	−1.5735	0.032006
Notch2	Notch homolog 2 (Drosophila)	−1.5881	0.002803
Ccna2	Cyclin A2	−1.6122	0.012739
Stag1	Stromal antigen 1	−1.6178	0.028532
Rad21	RAD21 homolog (S. pombe)	−1.6594	0.014072
Mcm2	Minichromosome maintenance complex component 2	−1.6613	0.013286
Cdkn1a	Cyclin-dependent kinase inhibitor 1A	−1.7021	0.028311
Rad9	RAD9 homolog (S. pombe)	−1.7319	0.04898
Skp2	S-phase kinase-associated protein 2 (p45)	−1.7621	0.029069
Ak1	Adenylate kinase 1	−1.8412	0.000319
RGD1566319	Similar to Sestrin 2 (Hi95)	−1.9417	0.000214
Apbb1	Amyloid beta (A4) precursor protein-binding. family B. member 1 (Fe65)	−1.9757	0.01365
Gpr132	G protein-coupled receptor 132	−1.9779	0.000082
Tp53	Tumor protein p53	−2.1997	0.003929
Prm1	Protamine 1	−2.2694	0.007761
Ccnf	Cyclin F	−3.3807	0.000503
Nek2	NIMA (never in mitosis gene a)-related expressed kinase 2	−3.8655	0.002508
Pkd1	Polycystic kidney disease 1 homolog (human)	−4.1911	0.000004
Tp63	Tumor protein p63	−4.8422	0.000526

Figure 4

Results of the PCR array for cell cycle related genes in the ZF fraction.

Clustergram showing the expression profile of significantly (p<0.05) altered genes related to the cell cycle in the adrenal ZF fraction after inhibition of the HPA axis with DEX for two days (50 µg/100 g BW), followed by ACTH, N-POMCMet, or N-POMCCys treatments (A). Correlation of up- or down-regulated genes in the ZF fraction after treatments, showing the number of genes regulated by both treatments with POMC-derived peptides (B). Up- or down-regulated genes related to specific cell cycle phases after ACTH, N-POMCMet, or N-POMCCys treatments (C). G1: G1 phase and G1/S transition; G2: G2 phase; S: S phase and DNA replication; M: M phase.

Table 3

Genes significantly regulated in the ZF fraction of the adrenal cortex after inhibition of the HPA axis followed by treatments with ACTH, N-POMCMet, or N-POMCCys.

ZF Fraction: ACTH
Gene Symbol	Gene	Fold Regulation	p-value
Nek2	NIMA (never in mitosis gene a)-related expressed kinase 2	3.3299	0.015864
LOC307231	Similar to nuclear factor of activated T-cells. cytoplasmic. calcineurin-dependent 1	2.6109	0.027357
Ppm1d	Protein phosphatase 1D magnesium-dependent. delta isoform	1.5109	0.000879
Casp3	Caspase 3	1.3435	0.022633
Tp53	Tumor protein p53	1.3065	0.001567
Stag1	Stromal antigen 1	1.1732	0.045706
Dnajc2	DnaJ (Hsp40) homolog. subfamily C. member 2	1.1606	0.003126
Mdm2	Mdm2 p53 binding protein homolog (mouse)	1.0758	0.009491
Inha	Inhibin alpha	−1.2838	0.046751
Tp63	Tumor protein p63	−1.4785	0.006269
Msh2	MutS homolog 2 (E. coli)	−1.5469	0.000832
Rad51	RAD51 homolog (RecA homolog. E. coli) (S. cerevisiae)	−1.5965	0.040077
Ppp3ca	Protein phosphatase 3. catalytic subunit. alpha isoform	−1.704	0.04028
Ccnd1	Cyclin D1	−1.7342	0.040145
Wee1	Wee 1 homolog (S. pombe)	−1.8408	0.014263
Camk2a	Calcium/calmodulin-dependent protein kinase II alpha	−2.2419	0.016674
Ccnf	Cyclin F	−2.6841	0.04902
Apbb1	Amyloid beta (A4) precursor protein-binding. family B. member 1 (Fe65)	−2.6949	0.0375
Prm1	Protamine 1	−3.3064	0.049452
ZF Fraction: N-POMCMet
Gene Symbol	Gene	Fold Regulation	p-value
LOC307231	Similar to nuclear factor of activated T-cells. cytoplasmic. calcineurin-dependent 1	3.9279	0.00014
Cdkn2b	Cyclin-dependent kinase inhibitor 2B	3.2928	0.045492
Notch2	Notch homolog 2 (Drosophila)	2.8467	0.043297
Nek2	NIMA (never in mitosis gene a)-related expressed kinase 2	2.7511	0.001391
Casp3	Caspase 3	1.5415	0.038784
Shc1	SHC (Src homology 2 domain containing) transforming protein 1	1.2958	0.042992
Rad21	RAD21 homolog (S. pombe)	1.257	0.023741
Tp53	Tumor protein p53	1.2521	0.002109
Stag1	Stromal antigen 1	1.248	0.021117
Dnajc2	DnaJ (Hsp40) homolog. subfamily C. member 2	1.152	0.001929
Mdm2	Mdm2 p53 binding protein homolog (mouse)	1.1368	0.030173
Brca2	Breast cancer 2	1.1087	0.040819
ZF Fraction: N-POMCCys
Gene Symbol	Gene	Fold Regulation	p-value
Nek2	NIMA (never in mitosis gene a)-related expressed kinase 2	3.3058	0.011916
Tp63	Tumor protein p63	2.7895	0.008098
Ccna1	Cyclin A1	2.4794	0.007717
Msh2	MutS homolog 2 (E. coli)	2.3214	0.018572
Sumo1	SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae)	2.2038	0.025152
Inha	Inhibin alpha	1.9185	0.000318
Sfn	Stratifin	1.8277	0.000008
Cdkn1a	Cyclin-dependent kinase inhibitor 1A	1.2397	0.016317
Ppm1d	Protein phosphatase 1D magnesium-dependent. delta isoform	1.21	0.024761
Ccnb1	Cyclin B1	−1.4845	0.039232
Camk2a	Calcium/calmodulin-dependent protein kinase II alpha	−1.9252	0.024671
Ccna2	Cyclin A2	−2.1361	0.026184
Slfn1	Schlafen 1	−2.2423	0.043104

ACTH and N-POMCMet increase Nek2b expression in the entire adrenal cortex

Based on previous data with PCR array, we chose Nek2 to evaluate the variation in the expression of some candidate genes on a protein level. This gene appeared down-regulated in the entire adrenal cortex after inhibition of the HPA axis and all three treatments up-regulated its expression in the ZF fraction. After treatments with either ACTH or N-POMCMet, there was an increase in Nek2b expression in the ZG fraction (2.35-fold and 2.31-fold, respectively) and also in the ZF fraction (1.93-fold and 1.85-fold, respectively) (Figure 5A). Immunohistochemistry showed increased Nek2b expression in the entire cortex following treatments with ACTH and N-POMCMet (Figure 5B and C). On the other hand, N-POMCCys treatment did not alter Nek2b expression, irrespective of the adrenal fraction analyzed (Figure 5D).

Figure 5

Analysis of Nek2b protein expression in adrenal ZF fraction and ZG fraction after inhibition of the HPA axis with DEX, followed by ACTH, N-POMCMet, or N-POMCCys treatments.

Adrenal glands were separated in two fractions (ZG and ZF), and total protein was extracted for immunoblotting analysis (A). Immunolocalization of Nek2b expression in the adrenal cortex after HPA inhibition followed by ACTH (B), N-POMCMet (C), or N-POMCCys (D) treatments. Adrenal sections were obtained from rats treated previously with DEX for two days (50 µg/100 g BW). Nek2b-positive cells were stained brown. Sections were counterstained with Harris’ hematoxylin and differentiated with a saturated solution of lithium carbonate. Bars 10 µm. *p<0.05, n = 3.

The expression of Notch proteins in the adrenal gland

Our PCR array data showed that Notch2 was up-regulated in the ZG and ZF fractions after ACTH or N-POMCMet, respectively. In order to determine the expression of the Notch2 protein, we performed an immunohistochemistry assay. Immunohistochemistry labeling for Notch2 showed no positive cells in the adrenal cortex or medulla, regardless of treatment. Positive Notch2 cells were present only in the adrenal capsule, and there was no modulation in their expression, irrespectively of treatment (Figure 6A). This result led us to evaluate the expression of two other Notch proteins in the adrenal gland, Notch1 and Notch3, even though we did not previously analyze their gene expression in the PCR array. The immunohistochemistry results for Notch1 revealed that this protein is expressed in both adrenal cortex and medulla (Figure 7A). Also, the expression of Notch1 is slightly reduced in the ZG of the cortex after HPA-axis inhibition with DEX (Figure 7B and C). ACTH and N-POMCMet treatments promoted an increase in Notch1 expression in sub-capsular cells (Figure 7D and E), whereas N-POMCCys treatment did not alter its expression anywhere in the cortex (Figure 7F). Notch3 protein expression analyses revealed that the adrenal medulla has remarkable positive staining for this protein, when compared to the cortex (Figure 8A). Further, the inhibition of the HPA axis by DEX promoted a decrease in the levels of Notch3 protein expression in the entire cortex (Figure 8B and C). After ACTH treatment, there was no significant modification in the expression of this protein (Figure 8D). However, after N-POMCMet or N-POMCCys treatments, we measured an increase in Notch3 expression (Figure 8E and F). The induction of Notch3 by N-POMCMet or N-POMCCys did not reestablish the Notch3 expression observed in the control with saline only.

Figure 6

Immunolocalization of Notch2 expression in the adrenal cortex.

Adrenal sections were obtained from rats treated with saline only. Notch2-positive cells are stained brown and indicated by arrows (A). Negative control without primary antibody (B). Sections were counterstained with Harris’ hematoxylin and differentiated with a saturated solution of lithium carbonate. Bars 10 µm.

Figure 7

Immunolocalization of Notch1 expression in the adrenal cortex.

Adrenal sections were obtained from rats treated with saline only (A and B) or two days with DEX (50 µg/100 g BW) followed by: saline (C), or ACTH (D), or N-POMCMet (E), or even N-POMCCys (F). Notch1-positive cells are stained in brown and indicated by arrows. Sections were counterstained with Harris’ hematoxylin and differentiated with a saturated solution of lithium carbonate. Bars 10 µm.

Figure 8

Immunolocalization of Notch3 expression in the adrenal cortex.

Adrenal sections were obtained from rats treated with saline only (A and B) or with DEX for two days (50 µg/100 g BW) followed by: saline (C), or ACTH (D), or N-POMCMet (E), or even N-POMCCys (F). Notch3-positive cells are stained in brown and indicated by arrows. Sections were counterstained with Harris’ hematoxylin and differentiated with a saturated solution of lithium carbonate. Bars 10 µm.

Discussion

In this study we found that three genes (Ccnb2, Camk2a, and Nek2) were negatively regulated throughout the adrenal cortex when the HPA axis was inhibited. Ccnb2 and Camk2a are related to the G2/M transition and Nek2 is associated with key processes of spindle checkpoint. Cyclin B2/CDK1 is a key kinase complex involved in the transition of phase G2/M and its inhibition. Cyclins B1 and B2 act at the same CDK complex, promoting the progression of the cell cycle, and cyclin B2 is able to compensate for the down-regulation of cyclin B1 during mitosis in human cells [14]. Cyclin B2 has been shown to be overexpressed in adrenocortical carcinoma and is thus a good candidate for distinguishing benign from malignant adrenocortical tumors [15]. Calcium/Calmodulin-Dependent Protein Kinase II Alpha (Camk2a) is essential for regulating G2/M and the metaphase-anaphase transition in many cell types [16]. It is a member of the family of serine/threonine protein kinases and is a downstream effector of the angiotensin II-triggered signaling cascade that synthesizes and releases aldosterone in the ZG-cells [17]. Moreover, aldosterone production stimulated by ACTH in ZG cells is triggered by an increase in Ca2+ influx, which activates Camk signaling [18]. Therefore, the repression of the HPA axis could, at least in part, compromise the production of aldosterone in ZG by down-regulating the expression of Camk2a.

Equally important is NEK gene expression, which encodes a serine/threonine enzyme involved in key processes such as the centrosome cycle, kinetochore–microtubule attachment, spindle checkpoint/assembly, chromosome condensation, and cytokinesis (for a review, see [19]). Furthermore, overexpression of NEK2 has been associated with breast tumorigenesis [20]. In 2009, Giordano et al. published a microarray dataset for adrenocortical tumors (carcinomas and adenomas) and normal adrenals [21] (freely available on the NCBI website under Gene Expression Omnibus Series accession number GSE10927, www.ncbi.nlm.nih.gov/geo/). When we analyzed these data, we observed that NEK2 is overexpressed in carcinomas compared to adenomas and normal adrenals (Figure S4). To our knowledge, this is the first report showing that Nek2 expression is associated with cell cycle regulation in adrenal glands.

Also, studies that screened the gene expression profile of serum-stimulated human fibroblasts showed that Nek2 mRNA levels are highest in S and G2 [22]. In the current study, we showed that Nek2b gene and protein are induced in both adrenal fractions after treatments with ACTH or N-POMCMet, suggesting that Nek2b could be associated with the control of adrenocortical cell proliferation, since these treatments promoted an increase in the number of cells in the S-phase [7]. To the best of our knowledge, this is the first report showing that Nek2 expression is associated with cell cycle regulation in adrenal glands.

Following HPA-axis inhibition, there was an increase in the expression of Tumor protein p53 (Tp53) and Cyclin-dependent kinase 1A (Cdkn1a) in the ZG fraction. Both of these genes are associated with cell cycle arrest. In the ZG fraction, the absence of POMC-derived peptides does not promote a decrease in the number of cells in the S-phase, even with the increase of these two genes associated with cell cycle arrest. On the other hand, the Wee1 gene was up-regulated in the ZF fraction. Wee1 kinase is able to phosphorylate and inhibit the cyclin B/CDK complex, which causes cell cycle arrest [23]. These data are in agreement with our own results showing the down-regulation of the cyclin B gene at the same time point and in the same adrenal fraction. Curiously, no gene was up-regulated in either fraction, reflecting the distinct peptide responses among adrenal cortex cells. The analysis of gene expression data plotted in the rat cell cycle pathway from the Kyoto Encyclopedia of Genes and Genomes (KEGG) shows that most cells in the ZG and ZF fractions seem to be in a different phase of the cell cycle, when analyzed at the same time point (Figures S2 and S3). Indeed, in the ZG fraction, HPA-axis inhibition down-regulates genes that are mainly related to the G1-S phases of the cell cycle, whereas in the ZF fraction, most repressed genes are in the G2 phase. Therefore, these data suggest that the zones comprising the adrenal cortex respond to inhibition of the HPA axis at different time points. This reinforces the notion of the independence of HPA axis control over the different zones of the adrenal cortex [24].

Regarding the effects of POMC-derived peptides in the adrenal cortex, we previously demonstrated that N-POMCMet peptide and ACTH promoted an increase in the number of cells in S-phase in all adrenal zones, whereas N-POMCCys was effective only in ZG and ZR [7]. These data are in contrast with previous observations in POMC-null mice in which peripheral administration of N-POMC peptide did not change adrenal growth, but caused a reduction in food intake and body weight [25]. Moreover, results published previously by the same group [26] showed that the synthetic peptide N-POMCCys is able to stimulate cell proliferation of tumor adrenocortical cells and primary culture of bovine adrenal glands. In addition, results from our group, which used primary cultures of rat adrenal cells, detected the involvement of MAPK-ERK signaling after stimulation with N-POMC peptides [9]. Consistent with these results, we showed that only N-POMCMet and ACTH up-regulated the expression of Nek2b in ZG and ZF, which highlights the differences between the two N-POMC peptides. Moreover, we observed that these mitotic treatments are able to increase the expression of genes related to the cohesin protein complex (Figure S3), which is associated with a late phase of cell division (for review see [27]). Interestingly, in N-POMCCys treatments, which do not stimulate ZF to enter the S-phase [7], the expression of the cohesin protein complex was not modulated.

The amino acid sequence of the N-terminal region of POMC is highly conserved between mammals [28], suggesting an important biological role for this peptide. The disulfide bridges in the N-terminal region of the native molecule induce the formation of a tertiary hairpin structure, which appears to be essential for accurate targeting of the peptide to the secretory region of the cell [29]. Here, the comparative analysis of the peptides’ effects on the expression of cell cycle genes in the ZG fraction, suggest that ZG cells are driven to different stages of the cell cycle, depending on the treatment (2h-ACTH or 2h-N-POMC). In fact, while 2h-ACTH treatment induced up-regulation of genes related to the G1-S transition, both 2h-N-POMC peptides down-regulated the genes associated with this phase. On the other hand, both 2h-N-POMC peptides up-regulated genes associated with the S-phase (Pcna and Gadd45; Figure S2).

The differences in gene expression profiles between the ZF and ZG fractions might be explained by the composition of the extracellular matrix (ECM) and the microenvironment of the adrenal zones [30]. There is some evidence that the ECM and integrins are differentially expressed throughout the rat adrenal cortex, and that the proliferative effect in vitro of ACTH in ZG and ZF cells depends on the composition of the substrate that these cells are exposed to [30]. Also, the vascularization of the adrenal gland, which begins at the periphery of the organ and reaches the marrow centripetally, promotes a diffusion gradient between the adrenal zones [31]. This diffusion gradient might be directly reflected in the concentration of POMC-derived peptides that each zone is influenced by, resulting in the observed differences in gene expression profiles.

Regarding Notch protein expression, we observed higher Notch1 expression in the subcapsular cells than in the rest of the cortex after ACTH and N-POMCMet treatments, but not after N-POMCCys treatment. Moreover, Notch2 appears to be expressed only in the capsular cells, irrespective of the treatment. The subcapsular and capsular cells of the adrenal cortex have been considered to be the main site of undifferentiated cells, involved in adrenocortical zonation, remodeling, and homeostasis (for a review, see [32]). It has recently been shown that Delta-like homologue 1 (Dlk1), which physically interacts with Notch1 [33], is expressed in the subcapsular region of the cortex and stimulates Gli1 expression in the mesenchymal cells of the adrenal capsule [34]. Therefore, after proliferative treatments, Notch1 is expressed in the same subcapsular region as Dlk1 and Sonic-Hedgehog (Shh), which suggests that this protein might be involved in the regulation of adrenocortical remodeling and homeostasis. Further studies must be conducted to elucidate the role of Notch1 in subcapsular cells. The Notch signaling pathway is one of the most altered pathways regarding adrenal tumors, suggesting that this pathway is also crucial for the proliferation of adrenocortical cells [35]. Interestingly, Notch3 is highly expressed in the adrenal medulla, where the presence of chromaffin progenitor cells has already been reported [36].

In conclusion, our study shows that the inhibition of the HPA axis represses the expression of Ccnb2, Camk2a, and Nek2 genes throughout the adrenal cortex, and that Nek2 is up-regulated after treatments with proliferative POMC-derived peptides. We also demonstrated that the zones of the adrenal cortex respond to HPA-axis inhibition and POMC-derived peptides at different times, reinforcing the notion that cells from the ZG and ZF fractions are in different phases of the cell cycle. Moreover, our results contribute to the understanding of the mechanisms triggered by N-POMC peptides and ACTH in genes associated with cell cycle regulation in adrenocortical cells.

Isoforms of Nek2 protein in commercial HeLa nuclear extracts, Y1 total extracts, rat adrenal gland extracts, and primary rat adrenal cell culture. Total proteins from Y1 cells, rat adrenal gland, and primary rat adrenal cell culture were extracted by using RIPA buffer.

(TIF)

Click here for additional data file.

Analysis of gene expression data from the ZG fraction plotted in rat cell cycle pathway from the Kyoto Encyclopedia of Genes and Genomes (KEGG). The genes highlighted in green are down-regulated and those in red are up-regulated.

(TIF)

Click here for additional data file.

Analysis of gene expression data from the ZF fraction plotted in rat cell cycle pathway from the Kyoto Encyclopedia of Genes and Genomes (KEGG). The genes highlighted in green are down-regulated and those in red are up-regulated.

(TIF)

Click here for additional data file.

The expression of comparing the microarray dataset from adrenocortical tumors, carcinomas and adenomas, and normal adrenals. The microarray dataset is published in [21] and is freely available on the website www.ncbi.nlm.nih.gov/geo/through Gene Expression Omnibus Series accession number GSE10927.

(TIF)

Click here for additional data file.

List of all genes analyzed in the RT-PCR-array (Rat Cell Cycle PARN-020 from Sabiosciences – Qiagen).

(DOC)

Click here for additional data file.